Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease

Link to article at PubMed

Neurodegener Dis Manag. 2019 Dec;9(6):289-299. doi: 10.2217/nmt-2019-0020. Epub 2019 Nov 5.


Amyloidosis is a group of diseases characterized by extracellular deposition of amyloid fibril complexes. Fibril deposition results in organ dysfunction and possible failure. Amyloidosis is regarded as a rare disease, but in general is underdiagnosed. The two main types of systemic amyloidosis are immunoglobulin light chain and transthyretin amyloidosis. The increased availability of noninvasive cardiac imaging, genetic testing and improved laboratory assays and protein identification methods have led to increased diagnosis. However, in many cases, the diagnosis is not made until the patient develops organ impairment. Earlier diagnosis is required to prevent irreversible organ failure. Novel treatments for immunoglobulin light chain and transthyretin amyloidosis that halt disease progression, prolong and increase quality of life have recently become available.

PMID:31686587 | DOI:10.2217/nmt-2019-0020

Leave a Reply

Your email address will not be published. Required fields are marked *